MCM3 and cancer: Considering that TMB, MSI, and neoantigen expression are common genomic alterations that are closely associated with cancer prognosis and immunotherapeutic responses (Ettinger et al., 2019; Ben-David and Amon, 2020; Picard et al., 2020), we measured the association between MCM3 and these alterations across cancers.